MX2017015302A - Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas. - Google Patents

Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.

Info

Publication number
MX2017015302A
MX2017015302A MX2017015302A MX2017015302A MX2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A MX 2017015302 A MX2017015302 A MX 2017015302A
Authority
MX
Mexico
Prior art keywords
activity
nucleotide repeat
reduction
reducing
target gene
Prior art date
Application number
MX2017015302A
Other languages
English (en)
Inventor
N Cohen Stanley
Deng Ning
Feng Yanan
Hao Cheng Tzu-
Yun WU Yun-
Chieh HSIEH Wen-
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2017015302A publication Critical patent/MX2017015302A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Los aspectos de la invención incluyen métodos para la reducción de la actividad perjudicial de un gen objetivo que contiene una repetición de nucleótidos (NR, por sus siglas en inglés) extendida mutante en una célula mediante el contacto de la célula con una cantidad eficaz de un agente nucleósido, así como también composiciones utilizadas en dichos métodos; la actividad perjudicial (por ejemplo, toxicidad y/o disfuncionalidad de los productos codificados por este) de un gen objetivo que contiene NR extendida mutante puede verse reducida en una variedad de diferentes formas, por ejemplo, mediante la reducción (y en algunos casos reducción diferencial, que incluye selectiva) la producción o actividad de los productos de expresión tóxica (por ejemplo, ARN o proteína) codificados por el gen objetivo; se proporcionan también kits y composiciones para poner en práctica los métodos objeto.
MX2017015302A 2015-05-29 2016-05-18 Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas. MX2017015302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562168558P 2015-05-29 2015-05-29
PCT/US2016/033116 WO2016196012A1 (en) 2015-05-29 2016-05-18 Nucleoside agents for the reduction of the deleterious activity of extended nucleotide repeat containing genes

Publications (1)

Publication Number Publication Date
MX2017015302A true MX2017015302A (es) 2018-03-28

Family

ID=57442140

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015302A MX2017015302A (es) 2015-05-29 2016-05-18 Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.

Country Status (16)

Country Link
US (1) US10675293B2 (es)
EP (1) EP3303588A4 (es)
JP (1) JP2018520111A (es)
KR (1) KR20180030461A (es)
CN (1) CN107614686A (es)
AU (1) AU2016270297B2 (es)
BR (1) BR112017022578A2 (es)
CA (1) CA2978521A1 (es)
CL (1) CL2017002608A1 (es)
CO (1) CO2017011617A2 (es)
CR (1) CR20170544A (es)
EA (1) EA201792261A1 (es)
IL (1) IL254304A0 (es)
MX (1) MX2017015302A (es)
SG (1) SG11201707513QA (es)
WO (1) WO2016196012A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6990369B2 (ja) * 2017-05-19 2022-02-03 国立大学法人 熊本大学 遺伝性腎疾患アルポート症候群治療薬に係る評価系
AU2018288771B2 (en) * 2017-06-19 2022-04-14 Thomas W. Sun Compounds for the reduction of the deleterious activity of extended nucleotide repeat containing genes
US10882821B1 (en) 2017-09-26 2021-01-05 The Board Of Trustees Of The Leland Stanford Junior University Enantiomeric compound for the reduction of the deleterious activity of extended nucleotide repeat containing genes
TWI796420B (zh) * 2018-01-22 2023-03-21 國立陽明交通大學 提升ｓｕｐｔ４ｈ在細胞中核苷酸重複序列擴張基因之轉錄調控能力的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5620978A (en) 1994-01-03 1997-04-15 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
PT1171137E (pt) 1999-02-23 2008-03-17 Univ California Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
EP1224199A1 (en) 1999-10-26 2002-07-24 Deltagen, Inc. Transgenic mice containing trp gene disruptions
US20050277133A1 (en) 2001-05-18 2005-12-15 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050096284A1 (en) 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20080176812A1 (en) 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
CA2500224C (en) 2002-09-25 2015-04-28 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
US20040152651A1 (en) 2002-11-01 2004-08-05 Rana Tariq M. Regulation of transcription elongation factors
JP2006515885A (ja) * 2003-01-17 2006-06-08 スレッシュオールド ファーマシューティカルズ， インコーポレイテッド 癌の処置のための併用療法
US20050037992A1 (en) 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
DK2821085T3 (da) 2003-09-12 2020-08-03 Univ Massachusetts Rna-interferens til behandling af "gain-of-function"-forstyrrelser
WO2006105038A2 (en) 2005-03-25 2006-10-05 The Uab Research Foundation Methods of altering gene expression and methods of treatment utilizing same
JP5461009B2 (ja) 2005-06-08 2014-04-02 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 非ペプチド及びペプチドｂｄｎｆニューロトロフィン類似体を用いた神経細胞生存促進法
WO2007022470A2 (en) 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
US8129357B2 (en) 2006-04-07 2012-03-06 Academia Sinica Method of making and using an adenosine analogue
US7375190B2 (en) 2006-09-19 2008-05-20 National Yang-Ming University Recombinant protein and method of screening for agents that modulate polypeptide aggregation
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
HUE033113T2 (en) 2009-09-11 2017-11-28 Ionis Pharmaceuticals Inc Modifying Huntingtin expression
US20120295863A1 (en) * 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
US20130059902A1 (en) 2010-02-08 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
US8569254B2 (en) 2010-12-10 2013-10-29 National Yang Ming University Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
US8618077B2 (en) * 2011-04-28 2013-12-31 Emory University Compositions and methods for treating fragile X premutation RVGG repeats-mediated toxicity
CA2850367C (en) 2011-09-30 2021-06-01 Tufts University Uridine diphosphate derivatives, compositions and methods for treating neurodegenerative disorders
WO2015061426A1 (en) * 2013-10-23 2015-04-30 Academia Sinica Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Also Published As

Publication number Publication date
EP3303588A1 (en) 2018-04-11
EP3303588A4 (en) 2019-01-23
EA201792261A1 (ru) 2018-04-30
AU2016270297B2 (en) 2019-12-12
CR20170544A (es) 2018-03-20
CN107614686A (zh) 2018-01-19
WO2016196012A1 (en) 2016-12-08
JP2018520111A (ja) 2018-07-26
SG11201707513QA (en) 2017-10-30
KR20180030461A (ko) 2018-03-23
IL254304A0 (en) 2017-11-30
CO2017011617A2 (es) 2018-02-09
US20180064744A1 (en) 2018-03-08
CL2017002608A1 (es) 2018-06-29
AU2016270297A1 (en) 2017-09-21
CA2978521A1 (en) 2016-12-08
BR112017022578A2 (pt) 2018-07-17
US10675293B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
MX2020013357A (es) Polimerasas, composiciones y metodos de uso.
MX2020013347A (es) Polimerasas, composiciones y metodos de uso.
PH12021550805A1 (en) Methods and Compositions for Editing RNAs
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
MX2022003116A (es) Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos.
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
WO2017044857A3 (en) Methods and compositions for the treatment of glaucoma
WO2017019660A8 (en) Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
MX2016009243A (es) Métodos de mutagénesis.
MX2020003339A (es) Arn guía de cpf1 modificado.
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
MX2021010668A (es) Proteinas de fusion de citoquinas.
MX2017015302A (es) Agentes nucleosidos para la reduccion de la actividad perjudicial de los genes que contienen repeticiones de nucleotidos extendidas.
WO2016065349A8 (en) Short non-coding protein regulatory rnas (sprrnas) and methods of use
MX2015015564A (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
MX2020000154A (es) Composiciones y métodos para inhibir la expresión de hmgb1.
MX2019005101A (es) Microarns modificados con 5-halouracilo y su uso en el tratamiento del cancer.
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
MX359337B (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
MX2019001239A (es) Deteccion de alto rendimiento basada en celulas para aptámeros.
MX2018012545A (es) Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso.
CA2986376C (en) Poxvirus-derived promoter, and vector comprising same
MX2019005149A (es) Arn bicatenario con modificaciones quimicas postranscripcionales.
PH12018500744A1 (en) Methods of preserving the biological activity of ribonucleic acids